University of Southern California USA
University of New South Wales Australia
Manal H Al Khanbashi
Higher College of Technology Oman
Pedro Sanchez Rovira
Xanit International Hospital Spain
David A Ligon
Oncology Fox LLC USA
Chiba University Japan
Pasteur Institute of Iran Iran
Sang Hyun Lee
Duke-NUS Medical School Singapore
Recommended Global Oncology & Cancer Conferences
Epigenetics and Cancer 2018
Epigenetics and Cancer 2018 conference is mainly focused on the progress of the scientific community against the cancer evolution, may it be research, clinical trials, and nursing. Hence, it showcases the new scientific and technical advances in comparison to the ancient theories with a vision of advanced innovation.
Who Should Attend??
Epigenetics and Cancer 2018 Conference is a novel discussion to unite overall recognized scholastics in the field of Oncology, Genetics, Genomics and Proteomics, Bioinformatics, Molecular Biology Researchers, Public wellbeing experts, Scientists, Academic researchers, Industry specialists, Scholars to exchange about the state of the Research and Development.
When the body's control mechanism stops working properly and the cells remain no longer normal, they start growing abnormally and uncontrollably, hence causing Cancer. Old cells do not die and instead grow out of control, forming new, abnormal cells. These extra cells may form a mass of tissue, called a tumor. A tumor can be benign and malignant as well. Benign tumors lack the ability to metastasize whereas malignant are life-threatening and metastasize which leads to cancer.
Throughout history, countless causes of cancer have been proposed including: angering the gods, fermenting or acidic lymph, chronic irritation, trauma, and infection. From the Humoral theory in the middle ages to the discovery of DNA structure in the mid-20th century, science has found many types and the causes of cancer. These theories stood unchallenged until when Galileo and Newton began to use the scientific method, which laid the foundations for the modern scientific study of disease.
Those theories and beliefs have evolved when you fast forward time nearly 200 years to 2012. And the World Health Organization’s International Agency for Research on Cancer (IARC) identified more than 100 chemical, physical, and biological carcinogens (agents that cause cancer by damaging DNA or disrupting cell metabolism).
To identify causes and develop strategies for prevention, diagnosis, treatment, and cure for cancer, the scientific community is indulged in research work all over the world. May it is research centers, institutes, companies, and hospitals, all contributions account a step by step progress against cancer.
Ranging from molecular bioscience to the clinical trials, Cancer research evaluates and compares applications of various Cancer treatments. Surgery, radiation therapy, chemotherapy, hormone therapy, immunotherapy and combined treatment modalities such as chemo-radiotherapy being such applications. The mid-1990s marks the shifting of clinical cancer research to therapies derived from biotechnology research, such as cancer immunotherapy and gene therapy.
The end step in a long process that begins in a research lab is Clinical Trials. After many years of research work to understand its effects on cancer cells in the lab and in animals, a new treatment is used with people in clinical trials.
Through clinical trials, doctors determine whether the new treatments are safe and effective and work better than current treatments. It helps in finding new ways to prevent and detect cancer and also to improve the quality of life for people during and after treatment.
Early treatments focused on improving surgical techniques for removing tumors. It was the 1900s when Radiation therapy and Chemotherapeutics came into the picture and were refined throughout the 20th century.
Emerging topics in cancer treatment research include:
- Anti-cancer vaccines
- Newer forms of chemotherapy
- Gene therapy
- Photodynamic therapy
- Radiation therapy
- Reoviridae (Reolysin drug therapy)
- Targeted therapy
- Natural killer cells can induce immunological memory
Research is being developed to modify their action against cancer.
The removal of tissue from the body is called Surgery. About 60% of patients will undergo some type of surgery to treat their cancer. In some cases, surgery is the only treatment required. It may also be combined with chemotherapy or radiation as part of an overall treatment plan. The place, type, size, stage of cancer and our general health, determine whether surgery is needed.
The several types of cancer surgery are:
- Curative surgery
- Preventive surgery
- Reconstructive surgery
- Staging surgery
- Supportive surgery
- Palliative surgery
- Minimally invasive surgery
Cancer genomics is the study of the complete set of DNA sequence and differences between gene expression of tumor cells and normal host cells. It aims to understand the genetic basis of tumor cell proliferation and the evolution of the cancer genome under mutation and selection by the body environment, the immune system and therapeutic interventions. Epigenomics is the study of the total epigenetic modifications on the genetic material of a cell.
The study of heritable changes in gene expression, excluding changes to the basic DNA arrangement (i.e., an adjustment in phenotype without an adjustment in genotype) is called Epigenetics. An epigenetic change is a normal, natural and characteristic occurrence yet can likewise be affected by a few factors including age, the environment/lifestyle, and illness state. Epigenetic modifications can show as normally as the way in which cells terminally separate to differentiate as liver cells, skin cells, etc. Alternately, epigenetic change can have all the more harming impacts that can bring illnesses, disease.
The study of epigenetic modifications of the Cancer cell genome, which does not bring a change in the nucleotide sequence, is called Cancer Epigenetics. Risk expectation, Prediction and Cancer prevention, growth counteractive actions are also promising and encouraging areas of Epigenetics. A high adequacy of demethylating agents was accounted for essentially in haematological malignancies in view of new conventions with the low dose and long exposure, and their utilization is presently being striven for strong tumors.
During the cell transformation to a cancerous cell, Epigenetic modifications are also important like genetic mutations. Their manipulation brings a great promising approach for prevention, detection, and therapy of Cancer.
Environmental contaminants and toxicants are far reaching all through the world and can incorporate different materials and chemicals, from by results of ignition to contamination trace metals and organic natural mixes utilized as a part of day by day life. Presentation of changing sums and sorts of these contaminants is connected to impacts on human well-being. The fields of natural wellbeing and toxicology have concentrated on bettering the comprehension of how these contaminants affect biological processes so that their wellbeing effects can be lessened or anticipated.
Numerous diseases are brought about by various types of alterations among different genes. Some of these progressions are hereditary changes that are passed along in families while some are mutations that happen due to various hazardous environmental factors.
A biomarker also called biological marker, generally refers to a measurable indicator of some biological state or condition, by which a particular pathological or physiological process, disease, etc., can be identified.
It can be a traceable substance that is introduced into an organism as a means to examine organ function or other aspects of health.
A cancer biomarker is a biological marker which indicates the presence of cancer in the body. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers are used for diagnosis, prognosis, and epidemiology of cancer.
Because they are expressed against a person's genetic background and environmental exposure, and epigenetic events occur early in cancer development, Epigenetic biomarkers are more advantageous over other types of biomarkers.
Epigenetic biomarkers potentially have numerous clinical applications in cancer intervention and treatment and significant implications for public health.
Types of epigenetic biomarkers:
- DNA methylation, circulating or noncirculating
- MicroRNA and other noncoding RNA
- Protein markers
For e.g., DNA methylation is one of the major epigenetic mechanisms and it is a genetic feature better reflecting disease development and, consequently, has the potential to become a more conclusive biomarker for detection and diagnosis of different diseases.
In the last few years, the market for Cancer profiling in Asia-Pacific region has seen huge development as a result of increasing incidence of Cancer, high demand for better healthcare services.
High prevalence of Cancer; expanding R&D subsidizing; expanding power of research exercises; expanding application for non-oncology illnesses; and developing organization between scholarly, biotechnology and pharmaceutical organizations are driving components of the Cancer Genomics and epigenetics market
Cancer Profiling Market is divided by Application, Diagnosis, Technique, Technology etc.
By Application, it consists of :
- Personalized Medicine
By Technique, it consists of :
By Technology, it consists of :
- Next-generation Sequencing
- In-situ Hybridization
It is estimated that the worldwide Cancer Profiling business sector is ready to achieve USD 61.87 Billion by 2021 from USD 25.82 Billion in 2016 according to the "Cancer Profiling Market".The following graph depicts the data pictorially.
Central point powering market development is increasing the number of malignancy cases over the globe.
Components, for example, the expanding interest for personalized medicine and point-of-care diagnostic tests in Cancer profiling are required to offer an extensive variety of development open doors for players in the tumor profiling market. The personalized medicine segment to represent the biggest share of the worldwide cancer profiling application showcase in 2016.
Across the board, continuous research in the part of Epigenetics in diseases and disorders in humans is fuelling the worldwide epigenetics drugs, diagnostic technologies, and indicative advances.
In light of research territories, the market for Epigenetics is fragmented into developmental biology, drug discovery, oncology, and other research areas. Other research areas include genome-wide regulatory mechanisms and research related to several metabolic and genetic diseases.
In light of geology, the market of Epigenetics is divided into North America, Europe, Asia, and the Rest of the World. North America is further sub-segmented into the U.S. Furthermore, Canada. In Asia, the degree for this present market's development is extending quickly. Asia represents a large portion of all cancer cases analyzed around the world. This makes helpful conditions for the development of the Epigenetic medications and diagnostics advertise in Asian nations, particularly China, Japan, Australia, and South Korea, with Japan in the prevailing position.
As per the National Cancer Institute, malignancy is among the main sources of death around the world, for which according to a recent review, epigenetic inhibitors comprise of the attributes and capacities which have the potential in cancer prevention and control. This element has given an impulse to the examination directed on epigenetics in the oncology business
In the estimated period between 2015 to 2020, the Epigenetics market is relied upon to stay as the number of new participants in this market will continue ascending with the consistent appearance of new innovations combined with upgraded highlights.
The Asia Pacific market is estimated to witness lucrative growth over the forecast period owing to, the presence of large prevalence of target diseases and high unmet medical needs. Technology progressions in the field of epigenetics particularly relating to the location of methylation markers identified with growth advancement is relied upon to enhance utilization rates.
Epigenetic reagents were the biggest market esteemed at over USD 1.2 billion in 2014 attributable to the expanding measure of R&D ventures and high utilization rates. Kits are relied upon to increase quick development sought after because of the expanding need for rapid and accurate detection techniques..
DNA methylation was the biggest innovation portion representing more than 47.0% income in 2014.Oncology was the biggest application showcase, with income esteemed at over USD 2.75 billion. The non-oncology segment is anticipated to register the fastest development of over 20.0% during the forecast period. The segment is dominated by metabolic diseases owing to, the growing base of the population suffering from diabetes and organ failure and increasing prevalence of sedentary lifestyle.
Owing to the increasing economic burden of diseases such as cancer and diabetes, governments across the world are advocating the adoption of early disease detection and diagnosis. Early cancer detection, especially, is being encouraged through screening kits. This is helping the development of the worldwide epigenetics drugs and indicative advancements advertise, states the report.
The overall business division of Epigenetics is divided in light of items, research domains, and topography. By item, the business area consolidates catalysts, instruments and consumables, packs and reagents.Instruments and consumables are further sub-segmented into mass spectrometers, cutting-edge sequencers, qPCRs, sonicators and different epigenetics instruments and consumables.Other research zones consolidate expansive managerial instruments and research related to metabolic and inherited diseases.
Epigenetics Product Outlook (Revenue, USD Million, 2015 – 2022)
Epigenetics Technology Outlook (Revenue, USD Million, 2015 – 2022)
· DNA Methylation
· Histone Methylation
· Histone Acetylation
· Large noncoding RNA
· MicroRNA Modification
· Chromatin structures
Epigenetics Application Outlook (Revenue, USD Million, 2015 – 2022)
· Solid Tumors
· Liquid Tumors
· Inflammatory Diseases
· Metabolic Diseases
· Infectious Diseases
· Cardiovascular Diseases
Epigenetics Market Regional Outlook (Revenue, USD Million, 2015 – 2022)
· North America
· Asia Pacific
· Latin America
· Middle East and Africa (MEA)
· South Africa
Past Conference Report
Epigenetics and Cancer 2017
Epigenetics and Biomarkers 2017: Past Conference Report
The success of the Epigenetics and Biomarkers 2017 conference has given us the prospect to bring the gathering one more time. Conferenceseries LLC hosted the “International Conference on Cancer Epigenetics and Biomarkers” during October 26-28, 2017 at Hyatt Regency Osaka, Japan.
The conference was focused on learning about Oncologists with the theme “From Novel therapies to Revolutionary Strategies, Diagnosis and Treatment”. The conference mainly directs towards addressing main issues like Prevention, Diagnosis, and Treatment diseases of the Organ-related Cancers and its innovative techniques. Epigenetics and Biomarkers 2017 is one of the most appreciated Cancer Conferences organized by Conferenceseries LLC. This Oncologists Meeting was discussed on methods and strategies related to management, quality improvement of Cancer as well as to explore the new ideas and concepts on a global scale and the topics include lung cancer, breast cancer, bone cancer, blood cancer, cervical cancer, colon-rectum cancer, prostate cancer, thyroid cancer.
The conference was embarked with an opening ceremony followed by Keynote sessions and followed by series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:
- Dr. Suraiya Rasheed, University of Southern California, United States
- Dr. Jenny Wang, University of New South Wales, Australia
- Dr. Manal H. Al Khanbashi, Higher College of Technology, Oman
- Dr. Pedro Sanchez Rovira, Xanit International Hospital, Spain
- Mr. David A Ligon, Oncology Fox, United States
- Dr. Atsushi Kaneda, Chiba University, Japan
- Dr. Glenn Deng, Stanford University School of Medicine, United States
- Dr. Ladan Teimoori-Toolabi, Molecular Medicine Department, Pasteur Institute of Iran, Iran
- Dr. Sang Hyun Lee, Duke-NUS Medical School, Singapore
- Dr. Jose Perez del Palacio, MEDINA Foundation, Spain
- Dr. Safana Salim Al Saidi, Ministry Of Health, Muscat
- Dr. In-Hye Jung, University of Ulsan College of Medicine, Seoul, South Korea
Conferencesereies LLC offers its heartfelt appreciation to Organizing Committee Members, dexterous of field, various outside experts, company representatives and is obliged to other eminent personalities who interlaced with Conferencesereies LLC and supported the conference in every aspect, without which the conference would not have been possible.
Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Epigenetics and Biomarkers 2017, Conferencesereies LLC would like to announce the commencement of the “2nd International Conference on Cancer Genetics and Epigenetics” to be held during May 24-25, 2018 Tokyo, Japan. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Oncology and Cancer Research.
For More details: https://epigeneticsconference.conferenceseries.com/
Let us meet again @ Epigenetics and Cancer 2018
Past Reports Gallery